<h4>Purpose</h4>HER2-targeted therapy has been incorporated into the standard neoadjuvant treatment (NAT) regimen for HER2-positive early-stage breast cancer, yet a subset of patients have shown a limited pathological response. The gene discussed is ERBB2; the disease is breast carcinoma.